Why the study?
Alterations in IGFBP3 may contribute to tumor occurrence and progression, prompting a review to provide a reference for the precise treatment of tumors.
This review highlights the role of IGFBP3 alterations in tumor pathogenesis and cell signaling, providing a reference for precise tumor treatment.
IGFBP3 alterations may modulate tumor progression; leaves open biomarker or therapeutic roles pending prospective studies.
Insulin-like growth factor binding protein 3 (IGFBP3) is the primary carrier of circulating insulin-like growth factors and is the most extensively studied protein among the six high-affinity insulin-like growth factor binding proteins. Alterations in IGFBP3 at both the transcriptional and post-translational levels may contribute to the occurrence and progression of tumors. The present review focused on the changes in expression levels of IGFBP3 in tumors, as well as the relationship between the activation and inhibition of associated cell signaling pathways, and alterations in cellular biological behavior, aiming to provide a reference for the precise treatment of tumors.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: